EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Efficacy, pharmacokinetics, and safety in the mouse and primate retina of dual AAV vectors for Usher syndrome type 1B

Rita Ferla, Fabio Dell'Aquila, Monica Doria, Maria Ferraiuolo, Alessia Noto, Fabiana Grazioli, Virginia Ammendola, Francesco Testa, Paolo Melillo, Carolina Iodice, Giulia Risca, Novella Tedesco und 9 weitere

Molecular Therapy - Methods & Clinical Development · 2023-03 · 28 · 396-411

DOI: 10.1016/j.omtm.2023.02.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy - Methods & Clinical Development, 2023-03. Verfasst von Rita Ferla und 20 weiteren Autor:innen. Beteiligte Einrichtung: Telethon Institute of Genetics and Medicine (TIGEM), Via Campi Flegrei 34, 80078 Pozzuoli, Italy. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gene therapy of Usher syndrome type 1B (USH1B) due to mutations in the large Myosin VIIA (MYO7A) gene is limited by the packaging capacity of adeno-associated viral (AAV) vectors. To overcome this, we have previously developed dual AAV8 vectors which encode human MYO7A (dual AAV8.MYO7A). Here we show that subretinal administration of 1.37E+9 to 1.37E+10 genome copies of a good-manufacturing-practice-like lot of dual AAV8.MYO7A improves the retinal defects of a mouse model of USH1B. The same lot was used in non-human primates at doses 1.6× and 4.3× the highest dose proposed for the clinical trial which was based on mouse efficacy data. Long-lasting alterations in retinal function and morphology were observed following subretinal administration of dual AAV8.MYO7A at the high dose. These findings were modest and improved over time in the low-dose group, as also observed in other studies involving the use of AAV8 in non-human primates and humans. Biodistribution and shedding studies confirmed the presence of vector DNA mainly in the visual pathway. Accordingly, we detected human MYO7A mRNA expression predominantly in the retina. Overall, these studies pave the way for the clinical translation of subretinal administration of dual AAV vectors in USH1B subjects.

Schlagwörter

Stichwörter der Autor:innen

Usher Syndrome type 1Bdual AAV vectorsgene therapynon-human primatesretinitis pigmentosa

Autor:innen und Institutionen

  • Telethon Institute of Genetics and Medicine (TIGEM), Via Campi Flegrei 34, 80078 Pozzuoli, Italy.
  • AAVantgarde BIO Srl, 20123 Milan, Italy.
  • ReiThera Srl, 00128 Rome, Italy.
  • Eye Clinic, Multidisciplinary Department of Medical Surgical and Dental Sciences, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy.
  • Center of Biostatistics for Clinical Epidemiology, School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.
  • Genethon, 91000 Evry, France.

Zitieren

APA

Ferla, R., Dell'Aquila, F., Doria, M., Ferraiuolo, M., Noto, A., Grazioli, F., Ammendola, V., Testa, F., Melillo, P., Iodice, C., Risca, G., Tedesco, N., le Brun, P. R., Surace, E. M., Simonelli, F., Galimberti, S., Valsecchi, M. G., Marteau, J. B., Veron, P., …, & Auricchio, A. (2023). Efficacy, pharmacokinetics, and safety in the mouse and primate retina of dual AAV vectors for Usher syndrome type 1B. Molecular Therapy - Methods & Clinical Development, 28, 396-411. https://doi.org/10.1016/j.omtm.2023.02.002

Vancouver

Ferla R, Dell'Aquila F, Doria M, Ferraiuolo M, Noto A, Grazioli F, et al. Efficacy, pharmacokinetics, and safety in the mouse and primate retina of dual AAV vectors for Usher syndrome type 1B. Molecular Therapy - Methods & Clinical Development. 2023;28:396-411. doi:10.1016/j.omtm.2023.02.002

BibTeX
@article{Ferla2023,
  author = {Ferla, Rita and Dell'Aquila, Fabio and Doria, Monica and Ferraiuolo, Maria and Noto, Alessia and Grazioli, Fabiana and Ammendola, Virginia and Testa, Francesco and Melillo, Paolo and Iodice, Carolina and Risca, Giulia and Tedesco, Novella and le Brun, Pierre Romain and Surace, Enrico Maria and Simonelli, Francesca and Galimberti, Stefania and Valsecchi, Maria Grazia and Marteau, Jean-Brice and Veron, Philippe and Colloca, Stefano and Auricchio, Alberto},
  title = {Efficacy, pharmacokinetics, and safety in the mouse and primate retina of dual AAV vectors for Usher syndrome type 1B},
  journal = {Molecular Therapy - Methods & Clinical Development},
  year = {2023},
  volume = {28},
  pages = {396--411},
  doi = {10.1016/j.omtm.2023.02.002}
}
Kostenlos starten →